New clinical and real-world data for Roche's Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss

Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema Real-world data reinforce that...

Related Keywords

United States ,United Kingdom ,London ,City Of ,Moorfields ,Ballymena ,Switzerland ,China ,Japan ,Ireland ,America ,Irish ,American ,Levi Garraway ,Nathalie Altermatt ,Bruno Eschli ,Birgit Masjost ,Gerard Tobin ,Loren Kalm ,Sabine Borngr ,Kirti Pandey ,Regulatory Agency ,National Eye Institute ,American Society Of Retina Specialists ,Roche Group Media Relations ,Drug Administration ,Genentech ,Head Of Global Product Development ,Novartis ,Roche Group ,Bright Focus Foundation ,Lancet Glob Health ,European Medicines Agency ,Chugai Pharmaceutical Co ,European Union ,Retina Specialists ,Annual Meeting ,Chief Medical Officer ,Global Product ,Disease Activity Criteria ,Dosing Interval Assignment ,Clinical Trial Patients With ,Study Design ,Diabetic Retinopathy Symposium ,Epiretinal Membrane Formation Over ,Late Breaking ,Reduces Macular Leakage ,Patients With ,Causes Rapid ,Sustained Intraocular Suppression ,Retinal Fluid Control With Faricimab ,Rapidly Improves Fluid Parameters ,China Subpopulation ,Treatment Patterns ,Diabetic Macular Edema Treated ,Delivery System With Ranibizumab ,Continuous Treatment ,Additional Results From ,Presentation Session ,Uveitic Macular Edema ,Preliminary Results From ,Infectious Diseases ,Port Delivery System ,Drug Administration Approved ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,American Society ,Demand Presentation ,Virtual Paper ,Poster Presentation ,States Food ,Lancet Glob ,Product Characteristics ,Markets ,